Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
Go back to Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 54.70 +0.70 (1.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.00 | 52 Week High | $77.12 | |||
| Open | $54.20 | 52 Week Low | $49.03 | |||
| Day High | $54.73 | P/E | 35.52 | |||
| Day Low | $54.00 | EPS | $1.54 | |||
| Volume | 16,238,704 | |||||
